Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affymax, Inc.
Affymax Reports Second Quarter 2008 Financial Results
September 5th, 2008
Affymax, Inc. (Nasdaq:AFFY) reported financial results for the second quarter ended June 30, 2008. The net loss for the second quarter of 2008 was $18.9 million compared to a net loss of $9.2 million for the second quarter of 2007. Affymax recognized revenue for the quarter ended June 30, 2008 of $19.1 million compared to $9.7 million for the quarter ended June 30, 2007. The increase in revenue was the result of increased collaboration revenue from its partnership with Takeda Pharmaceutical Company Limited, under their 2006 collaboration for development of Affymax's compound, Hematide(TM) and royalty payments from other parties. Research and...
Source: Health Business Week (2008-09-05)
|
